Skip to main content
. 2020 Mar 17;11(11):982–991. doi: 10.18632/oncotarget.27517

Table 3. Correlation between mutated plasma EGFR response and clinical response evaluated by RECIST criteria.

Plasma EGFR Response Clinical Response
Progressive disease Stable disease Partial response TOTAL
Poor responder 5 (71.4%) 2 (28.6%) 0 (0%) 7 (100%)
Good responder 3 (5.3%) 15 (26.3%) 39 (68.4%) 57 (100%)
TOTAL 8 (12.5%) 17 (26.6%) 39 (60.9%) 64 (100%)